Previous Article | Next Article 
Journal of Virology, October 2001, p. 9579-9584, Vol. 75, No. 20
0022-538X/01/$04.00+0 DOI: 10.1128/JVI.75.20.9579-9584.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Adenovirus Vector Designed for Expression of
Toxic Proteins
Dan
Edholm,
Magnus
Molin,
Edyta
Bajak, and
Göran
Akusjärvi*
Department of Medical Biochemistry and
Microbiology, BMC, Uppsala University, SE-751 23 Uppsala, Sweden
Received 4 June 2001/Accepted 6 July 2001
 |
ABSTRACT |
To construct recombinant adenoviruses expressing biologically
active proteins may be impossible, or result in a significant reduction
in virus yield, if the protein expressed has an inhibitory effect on
virus replication or cellular growth. To overcome this problem, we
previously designed adenovirus vectors expressing foreign proteins from
inducible promoters. However, during our work with a
replication-deficient virus expressing the ASF/SF2 splicing factor from
a progesterone antagonist-inducible gene cassette, we discovered that
ASF/SF2 was expressed at a significant level in the 293 producer cell
line, even in the absence of inducer. 293 cells code for adenovirus E1A
and E1B proteins and thus support the growth of E1-deficient
adenoviruses. Here we show that this background ASF/SF2 expression
results from a low level of E1A-mediated transactivation of the basal
promoter driving transgene expression. To overcome the problem of leaky
expression, we reconstructed a novel gene cassette that combines an
inducible promoter and a Lac repressor protein-based block to reduce
transcriptional elongation. We show that this novel vector system
dramatically reduced background transgene expression and therefore
should be useful for the rescue and propagation of high-titer stocks of recombinant adenoviruses expressing toxic proteins.
 |
INTRODUCTION |
Recombinant adenoviruses are one of
the preferred viral vectors used in gene therapy, cancer treatment, and
recombinant-protein production. Adenoviruses have several advantages
that make them suitable for gene transfer experiments (for reviews, see
references 8 and 9). For example, the virus
is relatively easy to manipulate in vitro and replicates efficiently in
permissive cells, thus enabling easy production of high-titer virus
stocks. Also, the cell surface receptor for adenovirus (reviewed in
reference 15) is expressed on most cells, making it
possible to infect a wide range of cell types.
In many protocols, the gene of interest is reconstructed into
transcription units that are under the control of a strong promoter, such as the promiscuous cytomegalovirus (CMV) promoter. This ensures that the transgene is expressed at a high level in many cell types. However, expression of endogenous genes in a cell is typically subject
to an intricate regulation in response to different stimuli. Thus,
constitutive high-level gene expression of a transgene may not be
physiological and may interfere with signaling systems in the cell and
lead to cellular toxicity. In fact, it has been technically difficult,
or impossible, to reconstruct recombinant adenoviruses carrying
genes for cytotoxic products, such as the vesicular stomatitis virus G
protein (21), the Fas ligand (17), human
tumor necrosis factor alpha (10), and the rabies virus glycoprotein (12), using constitutively active promoters,
because a high level of expression of these proteins is toxic for the cell. It is noteworthy that construction of a recombinant virus expressing the Fas ligand from an inducible Tet promoter was shown to
yield low-titer virus stocks, because even the basal level of Fas
ligand expression in 293 cells resulted in apoptosis of the
virus-producing cells (17). To produce this virus, it was necessary to establish a 293 cell line that was resistant to apoptosis. It is likely that the problem of transgene interference with virus growth is a more general problem that most often manifests itself as a
difficulty in producing high-titer stocks of recombinant adenoviruses.
To overcome this problem, we previously designed recombinant adenovirus
vector systems expressing the transgene from gene cassettes regulated
by inducible promoters (14). However, during our recent
work (13), in which we characterized the effect of overexpression of the essential serine- and arginine-rich (SR) protein ASF/SF2 on adenovirus replication, we became aware of an
unexpected complexity of our adenovirus-mediated inducible systems.
Infecting 293 cells with a recombinant virus expressing ASF/SF2 from
the progesterone antagonist-induced gene expression system (hereafter
referred to as the Prog system) resulted in a troublesome background
expression of ASF/SF2 in the absence of inducer late after infection
(13). Since ASF/SF2 has negative effects, particularly on
adenovirus alternative RNA splicing, this background expression was
sufficient to significantly perturb late viral mRNA accumulation. 293 cells (5) express the adenovirus E1A and E1B proteins, and
this is the producer cell line most commonly used to amplify
E1-deficient adenovirus vectors. Here we show that the background
expression of ASF/SF2 in 293 cells most likely results from the
E1A-289R protein (reviewed in reference 2) activating
transcription from the minimal TATA promoter element used in the Prog
system. Since the number of potential templates for transcription
increases tremendously due to viral DNA replication late after
infection, even a low level of E1A-mediated transcription initiation
may cause a significant amount of background transgene expression.
We and others have previously used inducible promoters to control
transgene expression (for examples, see references 10, 14,
17, and 20), and in one study, the Lac repressor
system was used to reduce transgene expression from the constitutively active CMV promoter (12). Here we combine both regulatory
systems into a powerful inducible gene cassette. We show that combining the inducible Prog promoter with a Lac repressor protein-based block to
transcription elongation dramatically reduces basal ASF/SF2 expression
in a 293 cell line expressing the Lac repressor protein. The effect was
observed at the level of ASF/SF2 protein expression as well as in a
significant relief of the previously observed phenotypic alterations of
ASF/SF2 in late viral mRNA accumulation (13).
Collectively, our results show that combining an inducible promoter
with a block to transcription elongation results in a dramatic
reduction in background transgene expression during virus growth in the
293 producer cell line. Thus, this may be an important factor that will
increase the success rate in construction and production of high-titer
stocks of recombinant viruses expressing toxic proteins that for
specific or general reasons have a strong negative effect on
virus multiplication.
 |
MATERIALS AND METHODS |
Establishment of a stable 293 cell line expressing LacI.
293
cells were transfected with plasmid pCMVLacI (Stratagene) by using the
Lipofectamine reagent (Gibco-BRL). The plasmid contains a hygromycin
resistance marker and codes for a LacI protein fused to a nuclear
localization signal (3). Selection for stably transfected
cells was initiated 72 h posttransfection by the addition of
hygromycin B (200 µg/ml) to the growth medium. After 7 days, when all
293 cells in an untransfected control dish were dead, the surviving
colonies of 293-LacI cells were transferred to a 96-well plate, where
they were extended in hygromycin-free medium. Clones that were shown to
express the LacI protein were further characterized by transfection of
plasmid pOP13CAT (Stratagene), which contains three Lac operator
sequences positioned upstream of the chloramphenicol acetyltransferase
(CAT) coding sequence. One cell line (denoted 293-LacI) was selected
for further experimentation based on its low level of basal expression
of CAT combined with a high level of CAT induced by addition of IPTG
(isopropyl-
-D-thiogalactopyranoside) to the culture medium.
Construction of a double-regulated recombinant adenovirus
expressing ASF/SF2.
The transfer plasmid pAdG5Trip(His)-ASF(Lac)
was constructed by cloning a BglII/NotI fragment
taken from pOP13CAT (Stratagene) into the MluI site in the
-globin intron in plasmid pAdG5Trip(His)-ASF (13). The
BglII/NotI fragment contains three lac
operator sequences. Plasmid pAdG5Trip(His)-ASF(Lac) was
reconstructed into a recombinant adenovirus essentially as described by
Stow (18). Briefly, a vector arm was produced by double
digestion of genomic Ad5-dl309 DNA with XbaI and
ClaI, followed by sucrose gradient purification of the long
right-hand 3.71- to 100-unit genomic fragment. Recombinant viruses were
generated by in vivo recombination. Thus, 5 µg of pAdG5Trip(His)- ASF(Lac) DNA was mixed with
1 µg of Ad5-dl309 vector arm and cotransfected by the calcium
phosphate coprecipitation technique to 293 cells (5).
Plaques typically appeared 5 to 6 days posttransfection. Recombinant
viruses were verified by restriction enzyme cleavage of
Hirt-extracted viral DNA (6). One positive plaque
was selected and purified by a second-round plaque assay. The final
reporter virus was named AdG5(His)-ASF(Lac). The activator virus
AdCMVProg has been described previously (14).
Purification of recombinant adenovirus.
High-titer stocks of
recombinant viruses were produced essentially as described previously
(7). Briefly, six 15-cm-diameter plates of 293 cells were
infected with approximately 5 PFU of recombinant virus per cell. Three
days postinfection (p.i.), when a clear cytopathic effect was visible,
cells were harvested by low-speed centrifugation. The cell pellet was
freeze-thawed once and resuspended in 2 ml of 0.1 M Tris-HCl, pH 8.0, followed by lysis with 0.1 volume of 5% Na-deoxycholate on ice for 30 min. Subsequently, the cell lysate was sonicated on ice, and virus was
purified by CsCl centrifugation. The virus band was collected and
dialyzed against 100 volumes of phosphate-buffered saline containing 1 mM CaCl2, 1 mM MgCl2, and
10% glycerol, using a Slide-A-Lyzer cassette (Pierce). The virus titer
was determined by plaque assay. Typical virus titers were
1010 PFU/ml.
Infections.
For infections, virus stocks were diluted in 1 ml of Dulbecco's modified Eagle's medium supplemented with 2% NCS
and used to infect one subconfluent 6-cm-diameter plate of 293 or
293-LacI cells, except for one experiment (see Fig. 3) in which a U2OS cell line expressing the adenovirus E1A transcription unit under the
transcriptional control of a Tet-ON-regulated promoter (see reference 14; kindly provided by C. Svensson) was used. In all experiments, 5 PFU of AdCMVProg and AdG5(His)-ASF or
AdG5(His)-ASF(Lac) per cell was used. The inoculum was removed
after a 1-h incubation at 37°C, and the cells were washed two times
with fresh medium followed by the addition of 4 ml of Dulbecco's
modified Eagle's medium supplemented with 10% NCS with or
without 0.5 µM RU 486 and/or 5 mM IPTG. Expression of
the E1A proteins was induced in the U2OS Tet-E1A cell line (see Fig. 3)
by addition of doxycycline to the culture medium to a final
concentration of 4 µM 8 h prior to infection.
Western blot analysis.
Protein extracts were prepared
18 h p.i. by lysis of infected cells with RIPA buffer (10 mM Tris
buffer, pH 7.4, 150 mM NaCl, 1% Nonidet P-40 (NP-40), 1%
deoxycholate, 0.1% sodium dodecyl sulfate (SDS), 1× Complete Protease
Inhibitor Cocktail [Boehringer-Mannheim]). Extracts were subjected to
SDS-12% polyacrylamide gel electrophoresis (PAGE) and transferred to
a nitrocellulose membrane by electroblotting. His-tagged ASF/SF2 was
detected using a six-His monoclonal antibody (Clontech). Filters were
treated as previously described (16), and proteins were
visualized by chemiluminscence (SuperSignal West Pico; Pierce) as
described in the manufacturer's protocol, using a horseradish
peroxidase-conjugated secondary antibody.
Northern blot analysis.
Total cytoplasmic RNA was prepared
by lysis with IsoB-NP-40 (10 mM Tris-HCl [pH 7.9], 150 mM
NaCl, 1.5 mM MgCl2, 1% NP-40) followed by two rounds of
phenol-chloroform-isoamyl alcohol and one extraction with
chloroform-isoamyl alcohol (1). Two micrograms of
cytoplasmic RNA was separated on a 1% agarose gel containing 2.2 M
formaldehyde, transferred to a nitrocellulose filter, and hybridized
with a DNA probe 32P labeled by random priming as
previously described (1). The Ad2 HindIII I
fragment (corresponding to adenovirus 31.5 to 37.3 map units) was used
as a probe to detect L1 mRNAs.
 |
RESULTS |
Construction of a novel gene cassette combining an inducible
promoter and a Lac repressor protein-based inhibition of transcription
elongation.
To silence the 293 cell-specific leaky expression of
the ASF/SF2 reporter gene from our RU 486-inducible Prog system
(13, 14), we introduced the LacSwitch II Inducible
Mammalian Expression System (Stratagene) into our viral vector system.
The approach relies on the construction of a stable 293 cell line
expressing the Lac repressor protein (293-LacI) and construction of a
new ASF/SF2 reporter virus in which three Lac operator sequences were inserted into the intron located downstream of the ASF/SF2 gene (Fig.
1). This virus was named
AdG5(His)-ASF(Lac). The idea was to use the Lac repressor protein to
restrict background ASF/SF2 expression, in the absence of inducer, by
preventing production of full-length mRNA from promiscuously initiated
transcripts.

View larger version (27K):
[in this window]
[in a new window]
|
FIG. 1.
Experimental strategy to silence basal transgene
expression. The promiscuous E1A transcriptional activator proteins are
a major cause of basal transgene expression in 293 cells (top). To
block E1A-mediated activation of the basal Prog promoter, three tandem
copies of the lac operator (3×LacO) were inserted into
the -globin intron located downstream of the ASF/SF2 coding sequence
(bottom). The Lac repressor protein expressed in the 293-LacI cell line
will reduce basal transgene expression by binding to the LacO sites and
prevent synthesis of full-length transcripts in the absence of inducer.
ss, splice site; p(A), poly(A).
|
|
A 293 cell line stably expressing the Lac repressor protein was
generated by transfection of 293 cells with the plasmid pCMVLacI,
which
codes for a Lac repressor protein fused to a C-terminal
nuclear
localization signal, and a hygromycin resistance marker
gene.
Following selection for hygromycin resistance, the surviving
clones
were screened for functional expression of the Lac repressor
protein as
described in Materials and Methods. More than 20 hygromycin-resistant
clones were screened using this assay system (data not shown).
One
clone, designated 293-LacI, was selected based on a low level
of basal
expression of CAT combined with a high level of CAT expression
induced
by addition of IPTG to the culture
medium.
High-level expression and tight control of ASF/SF2 expression in
293-LacI cells.
To determine whether our experimental approach
worked as predicted, we compared the level of background ASF/SF2
expression in 293-LacI cells double infected with equal numbers of PFU
of an activator and a reporter virus. Thus, activator virus, AdCMVProg (14) encoding a chimeric Gal4-VP16-progesterone
transactivator protein, was mixed with reporter virus, AdG5(His)-ASF or
AdG5(His)-ASF(Lac) expressing His-ASF/SF2 from a Gal4-regulated
promoter. Transcription of the His-ASF/SF2 gene was induced by addition
of RU 486 and/or IPTG to the culture medium. IPTG, which has no
negative effects on the growth of eukaryotic cells at concentrations
below 50 mM (4, 19), decreases the binding affinity of the
Lac repressor protein to the Lac operator sequence, thus relieving the
inhibitory effect of the Lac repressor protein on transcriptional elongation.
As shown in Fig.
2, coinfection of the
293-LacI cell line with AdG5(His)-ASF(Lac) or AdG5(His)-ASF and
AdCMVProg shows that
the Lac repressor protein was indeed able to
efficiently silence
the background expression of His-ASF/SF2 in
293-LacI cells (compare
lanes 4 and 7). Growth of the parental
AdG5(His)-ASF virus in
293-LacI cells resulted in a high level of
expression of His-ASF/SF2
even in the absence of inducer (lane 1). As
expected, the addition
of IPTG had no effect on His-ASF/SF2 expression
(lane 2), whereas
inclusion of RU 486 resulted in an approximately
sixfold induction
of His-ASF/SF2 expression (lane 3). In contrast,
infection of
the 293-LacI cell line with the AdG5(His)-ASF(Lac) virus
resulted,
as predicted, in a markedly reduced basal expression of
His-ASF/SF2
compared to infection with the parental AdG5(His)-ASF virus
(compare
lanes 1 and 4). As predicted, the addition of IPTG increased
His-ASF/SF2
expression in AdG5(His)-ASF(Lac)-infected cells to
essentially
the same level as seen in AdG5(His)-ASF-infected cells
(compare
lanes 1 and 2 with 5). A further inclusion of RU 486 resulted
in the same induced expression of His-ASF/SF2 as seen with the
parental
AdG5(His)-ASF virus (compare lanes 3 and 6). However,
since the basal
level of His-ASF/SF2 was markedly reduced, the
induction of ASF/SF2
increased to more than 60-fold in AdG5(His)-ASF(Lac)-infected
cells. As
expected, infection of normal 293 cells with the AdG5(His)-ASF(Lac)
virus resulted in a profile of His-ASF/SF2 expression (lanes 7
to 9)
identical to that seen in AdG5(His)-ASF-infected cells (lanes
1 to 3).

View larger version (43K):
[in this window]
[in a new window]
|
FIG. 2.
The 293-LacI cell line markedly reduces uninduced
transgene expression. 293-LacI or 293 cells were coinfected with
AdCMVProg and AdG5(His)-ASF(Lac) or AdG5(His)-ASF. His-ASF/SF2
expression was induced at the start of infection by the addition of RU
486 to the culture medium. Whole-cell extracts were prepared at 18 h p.i., separated on an SDS-12% PAGE gel, and probed with an anti-His
monoclonal antibody to detect His-ASF/SF2 expression. The lower gels
show a longer exposure of the filter to make it possible to compare the
background expression of His-ASF/SF2 in the absence of inducer in
293-LacI and 293 cells. + denotes addition of virus and/or
inducer.
|
|
Collectively, these results show that the Lac repressor protein
expressed in the 293-LacI cell line markedly reduces the background
of
His-ASF/SF2 expression in AdG5(His)- ASF(Lac) cells compared
to
the parental AdG5(His)-ASF virus. This effect was specific,
since
growth of the AdG5(His)-ASF(Lac) virus in the presence of
IPTG (Fig.
2,
lane 5) or in "normal" 293 cells (Fig.
2, lane 7)
showed the same
high level of background ASF/SF2 expression as
seen with the parental
AdG5(His)-ASF virus (Fig.
2, lane 1). Taken
together, these results
demonstrate that combining two strategies,
based on different
principles, to regulate gene expression represents
an effective
strategy to tighten the control of gene
expression.
The adenovirus E1A proteins activate basal transgene
expression.
The E1A transcriptional activator proteins expressed
in the 293 cell line have previously been shown to promiscuously
activate transcription from basal promoter elements (reviewed in
reference 2). We predicted that E1A-mediated activation of the
basal Prog promoter in the parental AdG5(His)-ASF virus was responsible for the low level of basal expression of His-ASF/SF2 that we previously observed in the 293 cell line (13) (Fig. 2). To test this
hypothesis, we infected a U2OS cell line expressing the adenovirus E1A
proteins under the inducible control of a Tet-ON-regulated promoter
with the AdG5(His)-ASF virus.
As shown in Fig.
3, His-ASF/SF2
expression is tightly regulated in U2OS-Tet E1A cells with a high level
of induced expression
(lane 3) and no detectable background expression
(lane 2). Interestingly,
induction of E1A expression in U2OS-Tet E1A
cells, by addition
of doxycycline to the culture medium, resulted in a
significant
expression of His-ASF/SF2 even in the absence of RU 486 (lane
5). The AdG5(His)-ASF virus should not efficiently replicate in
this cell line, since it lacks the E1A and E1B genes and U2OS-Tet
E1A
cells do not provide the E1B functions. That this is the case
is
supported by the observation that His-ASF/SF2 expression did
not
increase after E1A induction (compare lanes 3 and 6). If the
AdG5(His)-ASF virus did replicate, the increase in template numbers
would have resulted in more His-ASF/SF2 expression in lane 6.

View larger version (33K):
[in this window]
[in a new window]
|
FIG. 3.
Effect of adenovirus E1A on uninduced transgene
expression. AdG5(His)-ASF with or without AdCMVProg was used to infect
a U2OS cell line expressing the adenovirus E1A transcription unit from
a Tet-ON-inducible promoter. E1A expression was induced 8 h prior
to infection by addition of doxycycline (Dox) to the culture medium.
Whole-cell extracts were prepared 18 h p.i. Fifty micrograms of
total protein was separated on an SDS-12% PAGE gel and probed with an
anti-His monoclonal antibody. Lanes 1 and 4, mock-infected cells. + denotes addition of virus and/or inducer.
|
|
Based on these results, we conclude that a low level of E1A-mediated
activation of the basal Prog promoter causes an activation
of
His-ASF/SF2 expression even in the absence of RU 486. We propose
that
this E1A-mediated activation of basal transcription is the
major cause
of background transgene expression observed in the
293 cell line (Fig.
2).
ASF/SF2 inhibition of adenovirus alternative RNA splicing is to a
large extent relieved in 293-LacI cells.
We previously showed that
overexpression of the prototypical SR protein ASF/SF2 during lytic
growth of adenovirus almost completely blocked expression of mRNAs from
the major late transcription unit (13). In addition, we
showed that the basal (uninduced) expression of His-ASF/SF2 in
AdG5(His)-ASF-infected cells was sufficient to almost completely
inhibit late specific IIIa mRNA expression in 293 cells
(13). As shown in Fig. 2, infection of 293-LacI cells
with the modified AdG5(His)-ASF(Lac) virus strongly attenuates basal
ASF/SF2 expression. This reduction in basal ASF/SF2 expression would be
predicted to also relieve the negative effects of background ASF/SF2
expression on L1 alternative splicing. To test this hypothesis, we
compared the L1 mRNA profile in AdG5(His)-ASF- and
AdG5(His)-ASF(Lac)-infected 293-LacI cells.
As shown in Fig.
4B, inducing His-ASF/SF2
expression by the addition of RU 486 from the start of infection in
AdG5(His)-ASF-
or AdG5(His)-ASF(Lac)-infected cells resulted in an
almost complete
ablation of L1 mRNA expression (lanes 3 and 5). In
agreement with
our previous results (
13), both
accumulation of total L1 mRNA
and the relative expression of the IIIa
mRNA compared to the 52,55K
mRNA were significantly reduced in
AdG5(His)-ASF-infected cells
grown in the absence of RU 486 (lane 2)
compared to those in the
wild-type virus (lane 6). Also, the so-called
i-leader exon (Fig.
4A), which is selectively retained on L1 mRNAs
expressed early
after infection (reviewed in reference
11), was not
efficiently
spliced out, resulting in a predominant accumulation of the
52,55K+i
and the IIIa+i mRNA species (lane 2). These abnormalities in
L1
mRNA accumulation were to a large extent relieved in
AdG5(His)-ASF(Lac)-infected
cells. Thus, essentially wild-type levels
of total (sum of plus
and minus i-leader) 52,55K and IIIa mRNAs were
produced (compare
Fig.
4A, lanes 4 and 6). In fact, the
AdG5(His)-ASF(Lac) virus
produced, for unknown reasons, approximately
twofold more total
IIIa mRNA than the wild type. However, the relief on
L1 mRNA accumulation
was not complete, since a larger fraction of the
52,55K and the
IIIa mRNA populations still retained the i-leader exon
(lane 4)
compared to the wild type (lane 6). This is most likely
explained
by the fact that ASF/SF2 expression is dramatically reduced,
but
not extinguished, in 293-LacI cells in the absence of inducer(s)
(Fig.
2, lane 4, longer exposure).

View larger version (46K):
[in this window]
[in a new window]
|
FIG. 4.
Northern blot analysis of the adenovirus major late
region 1 mRNA expression. (A) Schematic representation of the
alternatively spliced mRNAs produced from the L1 transcription unit. L1
pre-mRNA splicing is temporally regulated, with different mRNA species
accumulating at early and late times of infection (reviewed in
reference 11). (B) 293-LacI cells were coinfected with
AdCMVProg and AdG5(His)-ASF(Lac) or AdG5(His)-ASF. Cytoplasmic RNA was
prepared 18 h p.i. Two micrograms of total cytoplasmic RNA was
separated on a denaturing 1% agarose gel and subsequently transferred
to a nitrocellulose filter. 52,55K and IIIa mRNA expression was
detected by hybridization with an L1-specific 32P-labeled
probe followed by autoradiography. Lane 1, mock-infected cells. + denotes addition of virus and/or inducer.
|
|
The LacI repressor protein does not interfere with transgene
expression from a recombinant virus grown in 293-LacI cells.
The
Lac repressor protein is a DNA binding protein and as such might be
incorporated into the AdG5(His)-ASF(Lac) virus capsid during virus
propagation in 293-LacI cells. This is an important issue, since Lac
repressor protein binding to viral DNA encapsidated in new virus
particles might restrict transgene expression and therefore require
inclusion of IPTG in subsequent gene transfer protocols. To check
whether this was necessary, an AdG5(His)-ASF(Lac) virus stock grown in
293-LacI cells was used to infect HeLa cells. As shown in Fig.
5, addition of RU 486 resulted in a
strong activation of His-ASF/SF2 expression, an activation that was not
further increased by addition of IPTG (compare lanes 3 and 4). This
result suggests that the LacI repressor protein does not become
incorporated to a significant degree into mature virus particles as a
protein binding to the Lac operator sequences.

View larger version (24K):
[in this window]
[in a new window]
|
FIG. 5.
The Lac repressor protein does not interfere with
transgene expression from a virus grown in 293-LacI cells. HeLa cells
were coinfected with an AdG5(His)-ASF(Lac) virus stock produced in
293-LacI cells and AdCMVProg in the presence or absence of IPTG.
Whole-cell lysates were prepared at 18 h p.i. One hundred
micrograms of total protein was separated on an SDS-12% PAGE gel and
probed with an anti-His monoclonal antibody detecting ASF/SF2. + denotes addition of virus and/or inducer.
|
|
 |
DISCUSSION |
We have previously shown that the RU 486-inducible Prog vector
system functions extraordinarily well in cell lines where the virus
does not replicate, reaching induction levels exceeding 600-fold
(14). However, during our work with a recombinant virus expressing the essential splicing factor ASF/SF2 (13), we
noted that the transgene was significantly expressed in the 293 cell line, even in the absence of inducer, causing significant abnormalities in late gene expression (13). Since 293 is the standard
cell line used for propagation of recombinant viruses, this background expression of the transgene may cause problems and reduce the virus
yield or, in the worst case, prevent reconstruction of viruses expressing toxic proteins (see the introduction).
Here we show that this troublesome background of transgene expression
is caused by the E1A transcriptional activator proteins expressed in
293 cells, which most likely activate transcription from the TATA
element present in the G5 minimal major late promoter driving reporter
gene expression (Fig. 3). Since viral DNA replication results in a
tremendous increase in the number of DNA templates available for
transcription, even a low level of E1A-mediated activation of transgene
expression may become troublesome at late times during infection. We
reasoned that it would be impossible to completely block the activity
of the promiscuous E1A transcriptional activator proteins in the 293 cell line by use of alternative minimal promoter elements, since the
E1A-289R protein has been shown to activate transcription from a basal
TATA promoter (reviewed in reference 2). We therefore
argued that combining two inducible systems, based on different
principles, might be a better way to tighten the control of gene
expression. Here we show that combining a LacI-based block to
transcription elongation and the inducible Prog-regulated gene cassette
indeed resulted in a dramatic reduction in the background expression of
the transgene in the 293-LacI cell line (Fig. 2). This reduction in
leaky transgene expression should increase the success rate when
recombinant adenoviruses expressing proteins that are highly toxic to
virus multiplication are constructed (see the introduction). Also, this
system has the advantage that it should allow for production of
high-titer stocks of recombinant viruses, which express proteins that,
for specific or general reasons, interfere with virus multiplication.
Admittedly, ASF/SF2 is not the ideal reporter gene in this set of
experiments, since ASF/SF2 overexpression is only moderately toxic to
adenovirus replication (13), causing a 60-fold reduction in virus yield at maximum induction. Also, growth of the
AdG5(His)-ASF(Lac) virus in 293-LacI cells caused a modest twofold
increase in virus yield compared to normal 293 cells (data not shown).
Nevertheless, we believe that our work using the ASF/SF virus proves
the principle that combining an inducible promoter and a block to
transcription elongation is an effective technique to tighten the
control of transgene expression. However, in its present version, this
system does not result in a complete shutoff of background transgene expression (Fig. 2, lane 4, longer exposure, and Fig. 4B, lane 4). Our
current experiments are aimed at refining the expression system to
further suppress background transgene expression.
 |
ACKNOWLEDGMENTS |
We thank C. Svensson for kindly providing the U2OS Tet-ON
E1A cell line. RU 486 was kindly provided by Roussel-Uclaf.
This work was supported by the Swedish Gene Therapy Program, the
Swedish Cancer Society, and the Göran Gustafsson Foundation for
Natural and Medical Research.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Medical Biochemistry and Microbiology, BMC, Box 582, Uppsala
University, SE-751 23 Uppsala, Sweden. Phone: 46-18-471 41 64. Fax:
46-18-50 98 76. E-mail: goran.akusjarvi{at}imbim.uu.se.
 |
REFERENCES |
| 1.
|
Ausubel, F. M.,
R. Brent,
R. E. Kingston,
D. D. Moore,
J. G. Seidman,
J. A. Smith, and K. Struhl.
1987.
Current protocols in molecular biology, p. 2.1.1-2.1.3.
In
K. Janssen (ed.), Current protocols. John Wiley & Sons, Inc., Boston, Mass.
|
| 2.
|
Berk, A. J.,
T. G. Boyer,
A. N. Kapanidis,
R. H. Ebright,
N. N. Kobayashi,
P. J. Horn,
S. M. Sullivan,
R. Koop,
M. A. Surby, and S. J. Triezenberg.
1998.
Mechanisms of viral activators.
Cold Spring Harbor Symp. Quant. Biol.
63:243-252[CrossRef][Medline].
|
| 3.
|
Fieck, A.,
D. L. Wyborski, and J. M. Short.
1992.
Modifications of the E.coli Lac repressor for expression in eukaryotic cells: effects of nuclear signal sequences on protein activity and nuclear accumulation.
Nucleic Acids Res.
20:1785-1791[Abstract/Free Full Text].
|
| 4.
|
Figge, J.,
C. Wright,
C. J. Collins,
T. M. Roberts, and D. M. Livingston.
1988.
Stringent regulation of stably integrated chloramphenicol acetyl transferase genes by E. coli lac repressor in monkey cells.
Cell
52:713-722[CrossRef][Medline].
|
| 5.
|
Graham, F. L.,
J. Smiley,
W. C. Russell, and R. Nairn.
1977.
Characteristics of a human cell line transformed by DNA from human adenovirus type 5.
J. Gen. Virol
36:59-74[Abstract/Free Full Text].
|
| 6.
|
Hirt, B.
1967.
Selective extraction of polyoma DNA from infected mouse cell cultures.
J. Mol. Biol.
26:365-369[CrossRef][Medline].
|
| 7.
|
Hitt, M.,
A. J. Bett,
L. Prevec, and F. L. Graham.
1994.
Construction and propagation of human adenovirus vectors, p. 479-490.
In
J. E. Celis (ed.), Cell biology: a laboratory handbook. Academic Press, San Diego, Calif.
|
| 8.
|
Hitt, M. M.,
C. L. Addison, and F. L. Graham.
1997.
Human adenovirus vectors for gene transfer into mammalian cells.
Adv. Pharmacol.
40:137-206.
|
| 9.
|
Hitt, M. M., and F. L. Graham.
2000.
Adenovirus vectors for human gene therapy.
Adv. Virus Res.
55:479-505[Medline].
|
| 10.
|
Hu, S. X.,
W. Ji,
Y. Zhou,
C. Logothetis, and H. J. Xu.
1997.
Development of an adenovirus vector with tetracycline-regulatable human tumor necrosis factor alpha gene expression.
Cancer Res.
57:3339-3343[Abstract/Free Full Text].
|
| 11.
|
Imperiale, M.,
G. Akusjärvi, and K. Leppard.
1995.
Post-transcriptional control of adenovirus gene expression, p. 139-171.
In
W. Doerfler, and P. Böhm (ed.), Current topics in microbiology and immunology. Springer Verlag, Berlin, Germany.
|
| 12.
|
Matthews, D. A.,
D. Cummings,
C. Evelegh,
F. L. Graham, and L. Prevec.
1999.
Development and use of a 293 cell line expressing lac repressor for the rescue of recombinant adenoviruses expressing high levels of rabies virus glycoprotein.
J. Gen. Virol.
80:345-353[Abstract].
|
| 13.
|
Molin, M., and G. Akusjärvi.
2000.
Overexpression of essential splicing factor ASF/SF2 blocks the temporal shift in adenovirus pre-mRNA splicing and reduces virus progeny formation.
J. Virol.
74:9002-9009[Abstract/Free Full Text].
|
| 14.
|
Molin, M.,
M. C. Shoshan,
K. Öhman-Forslund,
S. Linder, and G. Akusjärvi.
1998.
Two novel adenovirus vector systems permitting regulated protein expression in gene transfer experiments.
J. Virol.
72:8358-8361[Abstract/Free Full Text].
|
| 15.
|
Nemerow, G. R.
2000.
Cell receptors involved in adenovirus entry.
Virology
274:1-4[CrossRef][Medline].
|
| 16.
|
Petersen-Mahrt, S. K.,
C. Estmer,
C. Öhrmalm,
D. A. Matthews,
W. C. Russell, and G. Akusjärvi.
1999.
The splicing factor-associated protein, p32:regulates RNA splicing by inhibiting ASF/SF2 RNA binding and phosphorylation.
EMBO J.
18:1014-1024[CrossRef][Medline].
|
| 17.
|
Rubinchik, S.,
R. Ding,
A. J. Qiu,
F. Zhang, and J. Dong.
2000.
Adenoviral vector which delivers FasL-GFP fusion protein regulated by the tet-inducible expression system.
Gene Ther.
7:875-885[CrossRef][Medline].
|
| 18.
|
Stow, N. D.
1981.
Cloning of a DNA fragment from the left-hand terminus of the adenovirus type 2 genome and its use in site-directed mutagenesis.
J. Virol.
37:171-180[Abstract/Free Full Text].
|
| 19.
|
Wyborski, D. L., and J. M. Short.
1991.
Analysis of inducers of the E.coli lac repressor system in mammalian cells and whole animals.
Nucleic Acids Res.
19:4647-4653[Abstract/Free Full Text].
|
| 20.
|
Yoshida, Y.,
N. Emi, and H. Hamada.
1997.
VSV-G-pseudotyped retroviral packaging through adenovirus-mediated inducible gene expression.
Biochem. Biophys. Res. Commun.
232:379-382[CrossRef][Medline].
|
| 21.
|
Yoshida, Y., and H. Hamada.
1997.
Adenovirus-mediated inducible gene expression through tetracycline-controllable transactivator with nuclear localization signal.
Biochem. Biophys. Res. Commun.
230:426-430[CrossRef][Medline].
|
Journal of Virology, October 2001, p. 9579-9584, Vol. 75, No. 20
0022-538X/01/$04.00+0 DOI: 10.1128/JVI.75.20.9579-9584.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Lee, H.-J., Lee, Y.-J., Kwon, H.-C., Bae, S., Kim, S.-H., Min, J.-J., Cho, C.-K., Lee, Y.-S.
(2006). Radioprotective Effect of Heat Shock Protein 25 on Submandibular Glands of Rats. Am. J. Pathol.
169: 1601-1611
[Abstract]
[Full Text]
-
Ohrmalm, C., Akusjarvi, G.
(2006). Cellular Splicing and Transcription Regulatory Protein p32 Represses Adenovirus Major Late Transcription and Causes Hyperphosphorylation of RNA Polymerase II.. J. Virol.
80: 5010-5020
[Abstract]
[Full Text]
-
Haviv, Y. S., Takayama, K., Glasgow, J. N., Blackwell, J. L., Wang, M., Lei, X., Curiel, D. T.
(2002). A Model System for the Design of Armed Replicating Adenoviruses Using p53 as a Candidate Transgene. Molecular Cancer Therapeutics
1: 321-328
[Abstract]
[Full Text]